June 17, 2025 Rocky Mountain Chocolate Factory Reports Fiscal Fourth Quarter and Fiscal Year 2025 Financial Results Management to Host Conference Call Tomorrow at 9:00 a.m. ET DURANGO, Colo., June 17, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the "Company", "we", "RMC", or "Rocky Mountain Chocolate"), America's ChocolatierTM and a leading franchiser of a premium chocolate and confectionary retail store concept, is reporting financial and operating results for its fiscal ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2025 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to Commission File Number 0-14602 CYANOTECH CORPORATION (Exact name of registrant as specified in its charter) Nevada 91-1206026 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number: 001-41047 Chain Bridge I (Exact name of registrant as specified in its charter) | Cayman Islands | 95-1578955 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification Number) | | 8 The Green # 17538, Dover, DE | 19901 | | (Address of principal executive offices) | (Zip Code) | FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Chain Bridge I (Exact name of registrant as specified in its charter) | Cayman Islands | 95-1578955 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | ...

Distribution Information - The San Juan Basin Royalty Trust will not declare a monthly cash distribution for April due to the application of net proceeds of $3,435,269 to excess production costs[6] Production Costs - The excess production costs are a result of Hilcorp San Juan L.P.'s drilling of two new horizontal wells in 2024[6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 900 Stewart Avenue, Suite 301 ...

Sales Performance - Identical sales without fuel increased by 3.2% in Q1 2025 compared to Q1 2024[7] - Total company sales were $45.1 billion in Q1 2025, a decrease from $45.3 billion in Q1 2024, with a 3.7% increase excluding fuel and adjustment items[8] - Identical sales excluding fuel rose to $39,766 million in the first quarter of 2025, up 3.2% from $38,535 million in the same period of 2024[45] - eCommerce sales increased by 15% in Q1 2025[7] - Sales for Q1 2025 were $45,118 million, a slight decrease from $45,269 million in Q1 2024, representing a decline of approximately 0.3%[62] Profitability - Operating profit for Q1 2025 was $1,322 million, with adjusted FIFO operating profit at $1,518 million[6] - Adjusted EPS for Q1 2025 was $1.49, up from $1.43 in Q1 2024[6] - Gross profit for Q1 2025 reached $10,356 million, compared to $9,941 million in Q1 2024, marking an increase of about 4.2%[62] - Adjusted FIFO operating profit for Q1 2025 was $1,518 million, compared to $1,499 million in Q1 2024, indicating an increase of about 1.3%[58] - Operating profit for Q1 2025 was $1,322 million, slightly up from $1,294 million in Q1 2024, representing an increase of approximately 2.2%[58] Financial Guidance and Projections - Full-year 2025 guidance for identical sales without fuel has been updated to a range of 2.25% to 3.25%[17] - Adjusted free cash flow is projected to be between $2.8 billion and $3.0 billion for 2025[21] Debt and Liabilities - Kroger's net total debt to adjusted EBITDA ratio increased to 1.69 from 1.25 a year ago, with a target range of 2.30 to 2.50[16] - Total liabilities increased to $44,340 million in 2025 from $39,166 million in 2024, marking an increase of 13.2%[39] - Net total debt rose to $13,547 million in 2025, up 39.4% from $9,718 million in 2024[48] - Long-term debt, including obligations under finance leases, increased to $17,138 million in 2025 from $12,021 million in 2024, a rise of 42.5%[48] Cash Flow and Assets - Cash and temporary cash investments at the end of the period were $4,738 million, up from $2,863 million in 2024, reflecting a significant increase of 65.5%[41] - The net cash provided by operating activities was $2,149 million in 2025, down from $2,342 million in 2024, a decrease of 8.2%[41] - Total current assets increased to $15,765 million in 2025 from $14,163 million in 2024, representing an increase of 11.3%[39] Store Closures - Kroger plans to close approximately 60 stores over the next 18 months, recognizing a $100 million impairment charge, but expects a modest financial benefit from these closures[13] Shareholder Information - The total common shares outstanding decreased to 661 million at the end of the period in 2025 from 722 million in 2024, a reduction of 8.5%[39] - The average number of common shares used in diluted calculation decreased to 664 million in Q1 2025 from 727 million in Q1 2024[52] Earnings - Net earnings including noncontrolling interests decreased to $868 million in 2025 from $956 million in 2024, a decline of 9.2%[41] - Net earnings attributable to The Kroger Co. for Q1 2025 were $866 million, down from $947 million in Q1 2024, reflecting a decrease of approximately 8.5%[52] - Adjusted net earnings excluding adjustment items for Q1 2025 were $996 million, compared to $1,047 million in Q1 2024, indicating a decline of about 4.9%[52] Margins - Gross margin improved to 23.0% in Q1 2025 from 22.0% in Q1 2024, primarily due to the sale of Kroger Specialty Pharmacy[9] - Gross margin improved to 23.0% in Q1 2025, up from 22.0% in Q1 2024, reflecting a year-over-year increase of 1 percentage point[62]

Exhibit 99.1 Darden Restaurants Reports Fiscal 2025 Fourth Quarter and Full Year Results; Increases Quarterly Dividend; Authorizes New $1 Billion Share Repurchase Program; And Provides Fiscal 2026 Outlook ORLANDO, Fla., June 20, 2025 /PRNewswire/ -- Darden Restaurants, Inc. (NYSE:DRI) today reported its financial results for the fourth quarter and fiscal year ended May 25, 2025. Fourth Quarter 2025 Financial Highlights | 1 Consolidated Darden | 4.6% | | --- | --- | | Olive Garden | 6.9% | | LongHorn Steakho ...

CARMAX REPORTS FIRST QUARTER FISCAL YEAR 2026 RESULTS Richmond, Va., June 20, 2025 – CarMax, Inc. (NYSE:KMX) today reported results for the first quarter ended May 31, 2025. First Quarter Highlights: (1) • Net earnings per diluted share increased 42.3% to $1.38 from $0.97 a year ago. • Retail used unit sales increased 9.0% and comparable store used unit sales increased 8.1%; wholesale units increased 1.2%. • Total gross profit increased 12.8% to $893.6 million, driven by higher unit volumes and strong unit ...

Company Overview - Medtronic serves over 95,000 patients and operates in more than 150 countries, with a research and development spend of $2.7 billion[18]. - The company has over 95,000 full-time employees, with 44% based in the U.S. or Puerto Rico[39]. - The company's principal executive office is located in Ireland, while its main operational offices are in Minneapolis, Minnesota[167]. Innovation and Product Development - The company aims to accelerate innovation-driven growth through recent product launches and a robust pipeline, targeting strong revenue growth in attractive end markets[20]. - Medtronic's diverse product offerings across multiple portfolios position it well for future market expansion and innovation[19]. - The company is committed to maintaining technological leadership through extensive R&D efforts, participating in hundreds of clinical trials each fiscal year[51]. - The company emphasizes the integration of data, AI, and automation to improve patient care and operational efficiency[20]. - The company continues to support patients with HVAD devices despite halting the distribution of the HVAD System in June 2021[22]. Financial Performance - For fiscal year 2025, the company reported net income attributable to Medtronic of $4,662 million, with diluted EPS of $3.61 and an effective tax rate of 16.6%[191]. - Non-GAAP net income for fiscal year 2025 was $7,079 million, with diluted EPS of $5.49 and a non-GAAP effective tax rate of 16.7%[191]. - Free cash flow for fiscal year 2025 was $5,185 million, compared to $5,200 million in fiscal year 2024[194]. - Total net sales for fiscal year 2025 increased by 4% to $33,537 million, driven by growth in several segments including Cardiac Rhythm & Heart Failure and Diabetes[199]. Market Segments - Medtronic's Cardiovascular Portfolio includes advanced products such as implantable cardiac pacemakers and defibrillators, contributing significantly to its revenue streams[21][22]. - The Structural Heart & Aortic division offers therapies for heart valve disorders and aortic disease, enhancing the company's treatment capabilities[23]. - The Neuroscience Portfolio includes products for spinal and cranial technologies, addressing a wide range of neurological conditions[25]. - Medtronic's Medical Surgical Portfolio focuses on advanced surgical products and therapies, catering to healthcare systems and alternate site providers[32]. Regulatory Environment - The global regulatory environment is increasingly stringent, impacting the cost and time needed for product approvals[67]. - The EU Medical Device Regulation (EU MDR) became effective on May 26, 2021, with an extended implementation period for high-risk devices until the end of 2027[66]. - Compliance with evolving data privacy and cybersecurity regulations has resulted in increased costs and compliance challenges[70]. - Regulatory compliance is complex and any adverse actions from agencies like the U.S. FDA could materially affect the company's operations and market position[99]. Competition and Market Challenges - The company faces competition from both large manufacturers and small companies, as well as pharmaceutical companies producing alternative therapies[58]. - The healthcare industry consolidation and the rise of ambulatory surgery centers (ASCs) could lead to increased competition and downward pricing pressure on the company's products[156][158]. - Cost-containment measures in the healthcare industry may result in reduced sales of medical devices, as third-party payors may deny payment approvals for procedures involving the company's products[159]. Supply Chain and Operational Risks - Supply chain disruptions, particularly for components like semiconductors, have previously affected manufacturing operations[86]. - The company faces risks related to supply chain disruptions, including reliance on petroleum-based materials, which can significantly affect manufacturing costs and sales[88]. - The company has plans in place to ensure continuity of supply for components and raw materials, despite potential regulatory challenges[62]. Corporate Social Responsibility - The company has a strong commitment to patient-centered solutions, enhancing experiences for both patients and healthcare providers[20]. - The Medtronic Employee Emergency Assistance Fund has provided $4 million in grants over the last five years to employees facing financial hardships due to unexpected events[49]. - The company achieved 100% pay equity for gender and ethnically diverse employees in the U.S. and 99% globally for gender[43]. Future Outlook - The company announced plans to separate its Diabetes business, aiming to create a new independent, publicly traded company within 18 months of the announcement[38]. - The company intends to expand operations in emerging markets, which could expose it to additional risks and costs[149]. - Continued global adoption of the TYRX Envelope for implantable devices is expected to drive future growth in Cardiovascular[207].